Clinical trials: Metastasis Brain
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Cervicogenic Headache
Prevalence of Cervicogenic Headache in Lab Technicians
The purpose of the study is to determine the prevalence of cervicogenic headache among lab technicians
- Trial name
- NCT07067242
- Where
- Pakistan
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Elite College of Management Sciences, Gujranwala, Pakistan
Relapsed Neuroblastoma
Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma
HITC001 is a single institution study to evaluate the efficacy of using a standardized protocol of surgery and radiation for patients with brain metastases in relapsed neuroblastoma.
- Trial name
- NCT03406273
- Testing
- Cerebral Spinal (CS) radiation, Focal radiotherapy (SRS)
- Where
- United States
- Sponsor
- Giselle Sholler
Carotid Artery Stenosis
Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting
Remote limb ischemic preconditioning (RIPC) has neuro-protective and anti-inflammatory effects on ischemia- reperfusion injury. As the extent of its effect is unknown, the investigators will use clinical outcome, serum…
- Trial name
- NCT01654666
- Testing
- Remote ischemic preconditioning, Carotid Artery Stenting
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Ji Xunming
Chronic Migraine, Medication Overuse Headache
Mindfulness Therapy for Chronic Migraine
The aim is to assess the efficacy of adding on a Mindfulness-based therapy to pharmacological prophylaxis (experimental group: pharmacological prophylaxis + Mindfulness) against pharmacological prophylaxis only (control group) on…
- Trial name
- Mind-CM (NCT03671681)
- Testing
- Mindfulness, Prophylactic
- Where
- Italy
- Volunteers
- 177 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Solid Tumor Malignancies, Brain Metastasases
Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study
This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor, stratified into cohorts according to CNS disease…
- Conditions
- Solid Tumor Malignancies, Brain Metastasases, Leptomeningeal Disease (LMD), Central Nervous System
- Trial name
- ECLIPSE (NCT07476781)
- Testing
- One time CSF and blood sample
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Melanoma
Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
People with brain metastases from melanoma are offered different treatment options after local treatment of their brain metastases via surgery or stereotactic irradiation.
- Trial name
- WBRTMel (NCT01503827)
- Testing
- WBRT
- Where
- 23 sites in Australia, Norway and 1 more
- Volunteers
- 220 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Brain Metastases
GliaSite 1-3 Mets Study
This study has been designed to compile information on the efficacy of the GliaSite RTS combined with radiosurgery in the treatment of newly diagnosed metastatic brain tumors.
- Trial name
- NCT00589212
- Testing
- GliaSite Radiation Therapy System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Hologic, Inc.
Breast Cancer
TPI 287 in Breast Cancer Metastatic to the Brain
The goal of the first part of this clinical research study is to find the highest tolerable dose of TPI-287 in patients with breast cancer that has spread to the brain.
- Trial name
- NCT01332630
- Testing
- TPI 287, Dexamethasone, Benadryl
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer
Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases
The patients carrying a complicated primary lung cancer brain metastases die in less than 3 months of delay disease in the absence of treatment.
- Conditions
- Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer, Adenocarcinoma of Lung Metastatic to Brain, Cerebral Metastases
- Trial name
- METAL2 (NCT02162537)
- Testing
- Cisplatin, Pemetrexed, Bevacizumab
- Where
- 41 sites in France
- Volunteers
- 95 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Hepatic Encephalopathy, Decompensated Cirrhosis
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
Rationale Patients who recover from an episode of overt HE(OHE) are at risk of recurrent episodes of HE and persistent minimal hepatic encephalopathy, impacting their daily functioning and mental health.
- Conditions
- Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy
- Trial name
- HERB (NCT06538077)
- Testing
- Oral Branched chain Amino acid, Rifaximin 550 MG, Lactulose
- Where
- India
- Volunteers
- 336 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Lung Cancer (NSCLC)
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
The goal of this Phase II, multicenter, open-label, single-arm clinical trial is to evaluate the intracranial efficacy and safety of lorlatinib in adults with TKI-naïve, advanced ROS1-positive non-small cell lung cancer (NSCLC)…
- Trial name
- NCT07083687
- Testing
- Lorlatinib 100 mg
- Volunteers
- 21 people
- Sponsor
- Hunan Cancer Hospital
Non Small Cell Lung Cancer, Brain Metastases
A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
The purpose of this study is to evaluate the efficacy of icotinib alone or in combination with radiation therapy for NSCLC patients harboring EGFR mutation with brain metastases. The primary endpoint is overall survival .
- Trial name
- SMART (NCT04058704)
- Testing
- Icotinib, SRS/WBRT/HA-WBRT/SMART
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Metastatic Cancer, Radiation Toxicity
Melatonin and Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy.
- Conditions
- Metastatic Cancer, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031967
- Testing
- therapeutic melatonin, radiation therapy
- Where
- 234 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Melanoma, Metastatic Melanoma
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread…
- Trial name
- NCT04899921
- Testing
- Ipilimumab, Nivolumab, Troriluzole
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Dana-Farber Cancer Institute
Post-Dural Puncture Headache
Is Aminophylline More Effective Than Neostigmine/Atropine Mixture in the Treatment of Post-dural Puncture Headache
Objectives: To compare the safety and efficacy of IV aminophylline versus IV neostigmine/atropine mixture in the treatment of post-dural puncture headache (PDPH).
- Trial name
- RCT (NCT03997006)
- Testing
- IV Aminophylline, IV Neostigmine Methylsulfate + Atropine Sulphate
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Damanhour Teaching Hospital
Brain Metastasis, SRS
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
The goal of this clinical trial is to evaluate the efficacy of stereotactic radiotherapy in the treatment of brain metastases. The main question it aims to answer is: Did stereotactic radiotherapy improve LC rate in the treatment…
- Trial name
- NCT06852001
- Testing
- X-ray stereotactic radiotherapy for brain metastasis
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Recurrent Melanoma, Stage IV Melanoma
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
This phase I trial studies the side effects and best dose of ipilimumab when given together with whole brain radiation therapy or stereotactic radiosurgery in treating patients with melanoma with brain metastases.
- Conditions
- Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
- Trial name
- NCT01703507
- Testing
- Ipilimumab, Whole-Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery (SRS)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs, such as riluzole, may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT01018836
- Testing
- riluzole, whole-brain radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rutgers, The State University of New Jersey
Glioblastoma Multiforme, Brain Neoplasms
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme…
- Conditions
- Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04712721
- Testing
- 68Ga-FF58
- Where
- 2 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals